Their technology and expertise, combined with Thermo Fisher’s global commercial reach, is a strategic fit that enables us to better serve our transfection and stem cell research customers.
Thermo Fisher Scientific, the world leader in serving science, today announced it has signed a purchase agreement to acquire MTI-GlobalStem, a privately-held company that develops and commercializes leading-edge technology and reagents for cell transfection, neurobiology and stem cell research applications.
Completion of the transaction follows the receipt of all required regulatory approvals. Per the agreement, no further details of the transaction are being provided. Based in Gaithersburg, Md., MTI-GlobalStem will be folded into Thermo Fisher’s life sciences solutions segment.
“The addition of MTI-GlobalStem’s technology further strengthens Thermo Fisher’s leadership in biosciences and provides scientists around the world with access to a wider array of advanced research products designed to help accelerate discovery using cell models,” said Amy Butler, vice president and general manager of Cell Biology for Thermo Fisher Scientific. “Their technology and expertise, combined with Thermo Fisher’s global commercial reach, is a strategic fit that enables us to better serve our transfection and stem cell research customers.”
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.